There were 2,234 press releases posted in the last 24 hours and 359,258 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Immunomedics Presents Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Pretreated Metastatic Urothelial Cancer

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image